KindlyMD Announces Second Quarter 2024 Financial Results and Provides Shareholder Update

Rhea-AI Summary

KindlyMD (NASDAQ:KDLY) announced its Q2 2024 financial results and provided a shareholder update. Key highlights include:

1. Nearly 80% statewide comprehensive insurance coverage in Utah under contract with providers like Medicare, Select Health, Medicaid, and Blue Cross Blue Shield.

2. 163.7% sequential increase in reimbursement from insurance payors, totaling $126,325 in H1 2024 compared to $0 in H1 2023.

3. Completed IPO in June 2024 for net proceeds of $6.02 million.

4. Q2 2024 revenues decreased by 34.8% to $639,057, primarily due to a shift towards insurance billing.

5. Operating expenses increased by 6.0% to $1,676,250 in Q2 2024.

6. Net loss per share increased to $(0.26) in Q2 2024 from $(0.13) in Q2 2023.

7. As of June 30, 2024, cash and cash equivalents stood at $4.74 million with total working capital of $4.11 million.

Positive

• 163.7% sequential increase in reimbursement from insurance payors
• Achieved nearly 80% statewide comprehensive insurance coverage in Utah
• Completed IPO with net proceeds of $6.02 million
• Cash and cash equivalents of $4.74 million and total working capital of $4.11 million as of June 30, 2024

Negative

• Revenues decreased by 34.8% to $639,057 in Q2 2024 compared to Q2 2023
• Operating expenses increased by 6.0% to $1,676,250 in Q2 2024
• Net loss per share increased to $(0.26) in Q2 2024 from $(0.13) in Q2 2023

Financial Analyst

KindlyMD's Q2 2024 results present a mixed picture. The 163.7% sequential growth in insurance reimbursements to $91,553 is promising, signaling improved revenue quality. However, total revenue declined by 34.8% year-over-year to $639,057, primarily due to a shift from cash-pay to insurance billing.

The net loss per share widened to $(0.26) from $(0.13) year-over-year, indicating increased pressure on profitability. With $4.74 million in cash and $4.11 million in working capital post-IPO, KindlyMD has a runway to execute its growth strategy, but must accelerate revenue growth and control expenses to achieve profitability.

Healthcare Industry Analyst

KindlyMD's expansion of insurance coverage to 80% of Utah's market is a significant strategic move. Contracting with major providers like Medicare, Medicaid and Blue Cross Blue Shield positions the company for sustainable growth in a highly regulated industry.

The shift from cash-pay to insurance billing may cause short-term revenue fluctuations but should lead to more stable, recurring revenue streams long-term. The focus on accretive acquisitions in a fragmented market could accelerate growth and improve margins through economies of scale. However, successful integration of acquired clinics will be important for realizing these benefits.

Market Research Analyst

KindlyMD's position as Utah's first alternative medical treatment company with major insurance contracts gives it a first-mover advantage in a growing market. The collaboration with Curaleaf for patient education events demonstrates a commitment to market development and patient acquisition.

The company's registration on SAM.gov opens potential federal funding opportunities, which could be significant given the evolving regulatory landscape for cannabis. KindlyMD's comment on the DOJ's proposed reclassification of cannabis indicates proactive engagement with regulatory changes that could impact its business model and market size.

Company provides nearly 80% statewide comprehensive insurance coverage in Utah under contract with providers such as Medicare, Select Health, Medicaid, and Blue Cross Blue Shield

Reimbursement from insurance payors increased 163.7% sequentially and is expected to increase as a percentage of total revenue going forward

Reimbursements from insurance payors totaled $126,325 in first half of 2024 as compared to $0 during the first half of 2023

SALT LAKE CITY, UT / ACCESSWIRE / August 14, 2024 / KindlyMD, Inc. ("KindlyMD" or the "Company") (NASDAQ:KDLY), a patient-first healthcare and healthcare data company uniquely integrating traditional primary care and pain management strategies with integrated behavioral and alternative therapies, today announced its financial results for the second quarter ended June 30, 2024 and is providing a shareholder update.

Tim Pickett, PA-C, KindlyMD Founder and CEO, stated, "During the second quarter we successfully closed on our IPO for gross proceeds of approximately $6 million. While from a total revenue perspective during the quarter we did not yet yield the return on investment from the additional working capital we received, we are very pleased with the 163.7% sequential growth in reimbursement from insurance payors. As Utah's first alternative medical treatment company to contract under the state's top insurance payors, we are laser focused on growing this segment of our revenue stream. We are now proud to provide nearly 80% of statewide comprehensive insurance coverage to the Utah community, through top providers including Medicare, Select Health, Medicaid, and Blue Cross Blue Shield, according to the 2023 Utah Health Insurance Market Report. We are working to continue this growth trend, particularly as we invest in the acquisition of new patients to our facilities."

"Our team is also focused on aggressive growth via accretive acquisitions of clinics in Utah to expand our footprint. As a leader in the market, we see significant opportunity to potentially acquire profitable locations and integrate onto our platform driving operational synergies and margin expansion. The market is highly fragmented, and our potential pipeline remains robust. We look forward to updating our shareholders on our progress in the near future."

Operational Highlights:

• Completed IPO in June 2024 for net proceeds of $6.02 million

• Achieved nearly 80% statewide comprehensive insurance coverage in Utah according to the 2023 Utah Health Insurance Market Report

• Became Utah's first alternative medical treatment company to contract under the state's top insurance payors, which now include Medicare, Select Health and Medicaid and Blue Cross Blue Shield

• Collaborated with Curaleaf to expand patient education on medical cannabis care in Utah with community care events held at multiple Curaleaf Utah medical cannabis pharmacies

• Successfully registered on SAM.gov, the official U.S. federal funding platform

Subsequent Events:

• Submitted a comment to the U.S. Department of Justice, following its recent proposed rule to reclassify cannabis from Schedule I to Schedule III of the Controlled Substances Act

Financial Highlights for the Quarterly Period Ended June 30, 2024

The Company earned $91,553 in reimbursements from insurance payors during the three months ending June 30, 2024, an increase of 163.7% over the $34,722 earned for the three months ending March 31, 2024. The Company earned $126,325 in reimbursements from insurance payors during the six months ended June 30, 2024, as compared to $0 during the three and six months ended June 30, 2023.

Revenues decreased by $340,481, or 34.8%, to $639,057 for the three months ended June 30, 2024, from $979,538 for the three months ended June 30, 2023. The decrease in revenues is primarily attributed to a decrease in cash-pay patient care services as KindlyMD continues to shift toward insurance billing with commercial and governmental payers including Medicare, Medicaid, Select Health, Blue Cross Blue Shield, and other commercial payers compared to the prior period.

Operating expenses increased by $95,423, or 6.0%, to $1,676,250 for the three months ended June 30, 2024, from $1,580,827 for the three months ended June 30, 2023. The increase in operating expenses is primarily attributable to an increase in general and administrative expenses, salaries and wages, and cost of revenues.

Net loss per share decreased by $0.13, or 100.0%, to $(0.26) for the three months ended June 30, 2024, compared to $(0.13) for the three months ended June 30, 2023. KindlyMD management strives to look for opportunities to optimize revenue by increasing sales, acquiring additional clinics, improving margins, and controlling ongoing operating expenses.

As of June 30, 2024, the Company had cash and cash equivalents of $4.74 million and total working capital of $4.11 million.

In June 2024, KindlyMD completed its IPO for total net proceeds of $6.02 million, providing adequate liquidity and cash reserves to meet its obligations for at least the 12-month period following June 30, 2024, and to assist the Company in implementing its strategic operational business plans to create sustained cash flow generation thereafter.

As of August 9, 2024, the Company had 5,947,169 common shares outstanding.

About KindlyMD

KindlyMD™️ is a patient-first healthcare and healthcare data company uniquely integrating traditional primary care and pain management strategies with integrated behavioral and alternative therapies to offer patients comprehensive care and reduce the addiction and dependency of opioid use in the U.S. KindlyMD currently operates four centers, including the largest alternative pain treatment center in Utah. With a focus on holistic pain management through its specialty outpatient clinical services, including, where appropriate, the recommendation of medical cannabis by KindlyMD healthcare providers, KindlyMD is providing better patient health outcomes.

For more information, please visit www.kindlymd.com.

Forward-Looking Statements

This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified by the use of words such as "should," "may," "intends," "anticipates," "believes," "estimates," "projects," "forecasts," "expects," "plans," and "proposes." These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading "Risk Factors" in KindlyMD, Inc.'s Annual Report on Form 10-K for the fiscal year ended December 31, 2022. KindlyMD, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law. The information which appears on our websites and our social media platforms, including, but not limited to, Instagram and Facebook, is not part of this press release.

Investor Relations Contact:

Valter Pinto, Managing Director
KCSA Strategic Communications
(212) 896-1254
KindlyMD@KCSA.com

KINDLY MD, INC.
CONDENSED BALANCE SHEETS

		June 30, 2024				December 31, 2023
		(Unaudited)
ASSETS
Current Assets
Cash and cash equivalents		$	4,740,006			$	525,500
Accounts receivable			5,182				28,001
Inventories, net			3,825				63,202
Prepaid expenses and other current assets			305,655				225
Total Current Assets			5,054,668				616,928
Property and equipment, net			206,816				235,292
Operating lease right-of-use assets			184,177				235,706
Security deposits			11,276				11,276
TOTAL ASSETS		$	5,456,937			$	1,099,202
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Current Liabilities
Accounts payable and accrued expenses		$	628,749			$	329,810
Customer deposits			4,150				3,425
Current portion of operating lease liabilities			79,973				94,696
Current portion of finance lease liabilities			2,010				-
Current portion of notes payable, net			228,061				148,517
Derivative liability			-				238,000
Total Current Liabilities			942,943				814,448
Operating lease liabilities, net of current portion			124,651				164,295
Finance lease liabilities, net of current portion			8,635
Notes payable, net of current portion			-				228,871
TOTAL LIABILITIES			1,076,229				1,207,614
Stockholders' Equity (Deficit)
Preferred Stock, $0.001 par value, 10,000,000 shares authorized; none issued and outstanding as of June 30, 2024 and December 31, 2023			-				-
Common stock, $0.001 par value, 100,000,000 shares authorized; 5,939,516 and 4,617,798 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively			5,940				4,618
Additional paid-in capital			10,134,801				4,045,024
Accumulated deficit			(5,760,033	)			(4,158,054	)
TOTAL STOCKHOLDERS' EQUITY (DEFICIT)			4,380,708				(108,412	)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)		$	5,456,937			$	1,099,202

KINDLY MD, INC.
CONDENSED STATEMENTS OF OPERATIONS
(UNAUDITED)

		For the Three Months Ended June 30,								For the Six Months Ended June 30,
		2024				2023				2024				2023
Revenues		$	639,057			$	979,538			$	1,468,086			$	2,139,883
Operating Expenses
Cost of revenues			61,947				59,508				69,691				108,132
Salaries and wages			1,126,893				1,109,559				1,834,859				2,042,860
General and administrative			461,677				385,536				787,222				743,719
Depreciation			25,733				26,224				50,634				51,666
Total Operating Expenses			1,676,250				1,580,827				2,742,406				2,946,377
LOSS FROM OPERATIONS			(1,037,193	)			(601,289	)			(1,274,320	)			(806,494	)
Other Income (Expenses)
Other income			13,828				13,075				25,868				37,301
Interest expense			(318,450	)			(8,194	)			(375,689	)			(8,194	)
Loss on extinguishment of debt			(38,889	)							(38,889	)
Gain on change in fair value of derivative liability			61,051				-				61,051				-
Total Other Income (Expenses)			(282,460	)			4,881				(327,659	)			29,107
NET LOSS BEFORE INCOME TAXES			(1,319,653	)			(596,408	)			(1,601,979	)			(777,387	)
INCOME TAX EXPENSE			-				-				-				-
NET LOSS		$	(1,319,653	)		$	(596,408	)		$	(1,601,979	)		$	(777,387	)
LOSS PER COMMON SHARE - BASIC AND DILUTED		$	(0.26	)		$	(0.13	)		$	(0.33	)		$	(0.17	)
WEIGHTED-AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC AND DILUTED			5,009,956				4,455,912				4,813,877				4,445,714

KINDLY MD, INC.
CONDENSED STATEMENTS OF CASH FLOWS
(UNAUDITED)

		For the Six Months Ended June 30,
		2024				2023
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss		$	(1,601,979	)		$	(777,387	)
Adjustments to reconcile loss to net cash used in operating activities:
Stock-based compensation			15,500				338,021
Depreciation expense			50,634				51,666
Loss on extinguishment of debt			38,889				-
Gain on change in fair value of derivative liability			(61,051	)			-
Amortization of debt discounts			357,439				876
Amortization of right-of-use assets			51,529				61,589
Changes in operating assets and liabilities:
Accounts receivable			22,819				4,161
Inventories			59,377				(9,822	)
Prepaid expenses and other current assets			(305,430	)			11,039
Security deposits			-				731
Accounts payable and accrued expenses			298,939				106,668
Customer deposits			725				300
Operating lease liabilities			(54,367	)			(62,806	)
Net cash used in operating activities			(1,126,976	)			(274,964	)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment			(11,182	)			(14,420	)
Net cash used in investing activities			(11,182	)			(14,420	)
CASH FLOWS FROM FINANCING ACTIVITIES
Net proceeds from issuance of notes payable			45,000				-
Net proceeds from issuance of related party note payable							233,373
Net proceeds from issuance of common shares and warrants in connection with a public offering			5,860,650				-
Repayments of related party note payable			-				(20,282	)
Repayments of notes payable			(552,655	)			-
Repayments of finance lease liabilities			(331	)			-
Net cash provided by financing activities			5,352,664				213,091
NET CHANGE IN CASH AND CASH EQUIVALENTS			4,214,506				(76,293	)
CASH AND CASH EQUIVALENTS
Beginning of the period			525,500				186,918
End of the period		$	4,740,006			$	110,625
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash paid for interest		$	19,089			$	-
Cash paid for income taxes		$	-			$	-
NON-CASH INVESTING AND FINANCING ACTIVITIES
Debt discounts on notes payable		$	10,556			$	-
Debt discount on related party note payable		$	-			$	16,627
Fair value of derivative liability recognized upon issuance of notes payable		$	38,000			$	-
Extinguishment of derivative liability upon settlement of notes payable		$	214,949			$	-
Finance purchases of property and equipment		$	10,976			$	-

SOURCE: KindlyMD, Inc

View the original press release on accesswire.com

FAQ

What was KindlyMD's (KDLY) revenue for Q2 2024?

KindlyMD's revenue for Q2 2024 was $639,057, a decrease of 34.8% compared to Q2 2023.

How much did KindlyMD (KDLY) raise in its IPO in June 2024?

KindlyMD raised net proceeds of $6.02 million from its IPO in June 2024.

What was the growth in insurance reimbursements for KindlyMD (KDLY) in Q2 2024?

KindlyMD saw a 163.7% sequential increase in reimbursement from insurance payors in Q2 2024.

What is KindlyMD's (KDLY) cash position as of June 30, 2024?

As of June 30, 2024, KindlyMD had cash and cash equivalents of $4.74 million and total working capital of $4.11 million.